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We conducted a phase II trial of triplet chemotherapy consisting of vinorelbine, gemcitabine, and cisplatin in patients with
advanced non-small cell lung cancer to assess its efﬁcacy and toxicity. Thirty-three patients with chemotherapy-naı ¨ve stage IIIB
disease (n=8), stage IV disease (n=23), or recurrence after surgical resection (n=2) were given intravenous infusions of
vinorelbine 25 mg m
72, gemcitabine 1000 mg m
72, and cisplatin 40 mg m
72 on days 1 and 8 at 3-week intervals. There
were 16 partial responses, and the objective response rate was 48% (95% conﬁdence interval: 31–66%). The median survival
time was 13.5 months (95% conﬁdence interval: 10.6–16.4 months), and the one-year survival rate was 61%. Grade 4
haematologic toxicity consisted of neutropenia in 72% of patients, and febrile neutropenia occurred in 42% of the patients.
There was one toxic death, and it was attributed to neutropenic fever and haemoptysis. Autopsy revealed diffuse pulmonary
haemorrhage secondary to bacterial abscesses and vasculitis in both lungs. The common nonhaematologic toxicities included
grade 2–3 nausea (39%) and vomiting (18%). Triplet chemotherapy containing vinorelbine, gemcitabine, and cisplatin is
effective in the treatment of chemo-na ¨ive patients with advanced non-small cell lung cancer, but produces unacceptable
frequent febrile neutropenia.
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Lung cancer is a leading cause of cancer-related deaths in indus-
trialised countries, including Japan, where 54000 people died of
lung cancer in 2000. Non-small cell lung cancer (NSCLC) accounts
for approximately 80% of lung cancers, and approximately 70% of
patients present with locally advanced or metastatic disease. Meta-
analysis demonstrated that cisplatin-based chemotherapy yielded a
modest survival beneﬁt in advanced NSCLC (Grilli et al, 1993;
Souquet et al, 1993; Non-Small Cell Lung Cancer Collaborative
Group, 1995; Marino et al, 1994).
In the 1990’s, several new agents, including vinorelbine, gemci-
tabine, paclitaxel, docetaxel, and irinotecan, became available for
the treatment of NSCLC. Vinorelbine or gemcitabine combined
with cisplatin was found to result in longer survival than cisplatin
alone or vindesine plus cisplatin (Le Chevalier et al, 1994; Wozniak
et al, 1998; Sandler et al, 2000). Paclitaxel plus cisplatin was also
superior to etoposide plus cisplatin (Bonomi et al, 2000). The
Southwest Oncology Group (SWOG) conducted a randomised
phase III trial in advanced NSCLC to compare vinorelbine plus
cisplatin with paclitaxel plus carboplatin (Kelly et al, 2001), but
there was no signiﬁcant difference between the two arms with
respect to response rate, survival, or quality of life. The Eastern
Cooperative Oncology Group (ECOG) conducted a randomised
phase III trial in advanced NSCLC comparing three platinum-
based combination regimens containing gemcitabine, paclitaxel,
and docetaxel to a reference regimen of paclitaxel plus cisplatin
(Schiller et al, 2002), but none of the regimens, i.e. gemcitabine
plus cisplatin, paclitaxel plus carboplatin, docetaxel plus cisplatin
yielded longer survival than paclitaxel plus cisplatin. Irinotecan
plus cisplatin yielded longer survival than vindesine plus cisplatin
in stage IV NSCLC (Fukuoka et al, 2000). As a result, each of these
new agents plus cisplatin and paclitaxel plus carboplatin have
become the standard regimens for advanced NSCLC, but survival
with these doublet chemotherapies is not satisfactory.
Triplet chemotherapy or sequential chemotherapy with more
than two agents has been investigated to surpass standard doublet
chemotherapy. Triplet chemotherapy containing old agents has
never been superior to doublet chemotherapy in advanced NSCLC.
The activity of the new agents, however, has encouraged the devel-
opment and evaluation of new triplet combinations. Recently,
Comella et al (2000, 2001) reported promising activity and safety
of triplet combination including cisplatin, vinorelbine, plus gemci-
tabine, and cisplatin, gemcitabine, plus paclitaxel. These triplet
combinations yielded better survival than cisplatin plus vinorelbine
and cisplatin plus gemcitabine. Cisplatin, vinorelbine, plus gemcita-
bine was followed by a median survival time of 51 weeks, a 45% 1-
year survival rate, and 45% grade 3 or 4 neutropenia with no toxic
deaths. We considered it necessary to evaluate this regimen with
respect to its efﬁcacy and toxicity proﬁle. The primary end point
of this phase II trial was response rate, and the secondary end
points were toxicity and survival.
PATIENTS AND METHODS
Patient population
Patients were required to have histologically or cytologically
conﬁrmed stage IIIB (no indications for curative thoracic radia-
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www.bjcancer.comtion therapy for malignant pleural or pericardial effusion and/or a
too wide radiation ﬁeld) or stage IV NSCLC. Recurrences after
surgical resection were permitted. Other criteria included: (1)
age 20 years or more but less than 75 years; (2) ECOG perfor-
mance status (PS) 0 or 1; (3) measurable disease; (4) adequate
organ function (i.e., total bilirubin 41.1, AST and ALT
460 IU l
71, serum creatinine 41.2 mg dl
71, creatinine clearance
560 ml min
71, leukocyte count 4000–12000 mm
73, neutrophil
count 52000 mm
73, haemoglobin 59.0 g dl
71, and platelets
5100000 mm
73); (5) no prior chemotherapy or radiotherapy;
(6) no severe heart disease or uncontrolled angina; (7) no cardiac
infarction within the previous 6 months; (8) no uncontrolled
diabetes mellitus; (9) no active infection; (10) no active concomi-
tant malignancy; (11) no pregnancy or breast-feeding. No
palliative bone or brain radiotherapy was allowed. All patients
were required to provide written informed consent, and the insti-
tutional review board at the National Cancer Center approved the
protocol.
Treatment plan
Treatment was started within a week after enrolment in the study.
Patients received vinorelbine (25 mg m
72) diluted in 50 ml
normal saline as a 5- to 10-min intravenous infusion with
16 mg of dexamethasone and 3 mg of granisetron immediately
prior to vinorelbine infusion. Immediately after completion of
the vinorelbine infusion, ﬂushing was performed with 100 ml
normal saline over 20 min to prevent phlebitis. Gemcitabine
(1000 mg m
72) diluted in 100 ml normal saline was then intrave-
nously infused over 30 min. Finally, cisplatin (40 mg m
72) was
administered with 1500 ml of normal saline as a 30-min intrave-
nous infusion over 31
2 h. Vinorelbine, gemcitabine, and cisplatin
were administered on days 1 and 8. Treatment was repeated every
3 weeks. None of the drugs was administered if WBC
52500 mm
73 and/or platelets 550000 mm
73. Only vinorelbine
and gemcitabine were administered if serum creatinine
41.5 mg dl
71. In the event of grade 4 leukopenia or thrombocy-
topenia, non-haematologic grade 3 or more toxicities, and/or
omission of the treatment on day 8, the doses of all three drugs
were reduced by 20% in the next course of chemotherapy. If
serum creatinine increased to 2.0 mg dl
71 or more, only cisplatin
was reduced, by 20%, in the next course of chemotherapy. The
next course of chemotherapy was started if the following criteria
were met: WBC 53000 mm
73, platelets 575000 mm
73, AST
and ALT 42 times the upper limit of normal, ECOG PS 0-2,
and afebrile. Vinorelbine and gemcitabine alone were administered
in the next course if only the serum creatinine criterion was not
satisﬁed after delaying the next course for up to 6 weeks. Therapy
was continued for at least three courses unless the patient experi-
enced unacceptable toxicity or had progressive disease. The
maximum number of courses was six.
Study evaluations
Pretreatment evaluations consisted of a complete medical history,
determination of performance status, physical examination, haema-
tologic and biochemical proﬁles, electrocardiogram, chest X-ray,
bone scan, and computed tomography (CT) scan of the chest,
ultrasound or CT scan of the abdomen, and magnetic resonance
imaging (MRI) or CT scan of the whole brain. Evaluations
performed weekly were biochemistry, complete blood cell, platelet,
and leukocyte differential counts, physical examination, determina-
tion of performance status, and toxicity assessment. Imaging
studies were performed to assess objective response after every
two treatment courses.
Response and toxicity criteria
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
were used (Therasse et al, 2000). The target lesions were deﬁned as
52 cm in longest diameter on computed tomographic scans. A
complete response (CR) was deﬁned as the complete disappearance
of all clinically detectable tumours for at least 4 weeks. A partial
response (PR) was deﬁned as an at least 30% decrease in the
sum of the longest diameters of the target lesions for more than
4 weeks with no new area of malignant disease. Progressive disease
(PD) indicated at least a 20% increase in the sum of the longest
diameter of target lesions or a new malignant lesion. Stable disease
(SD) was deﬁned as insufﬁcient shrinkage to qualify for PR and
insufﬁcient increase to qualify for PD. Toxicity was graded accord-
ing to the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) version 2.0.
Statistical analysis
In accordance with the minimax two-stage phase II study design by
Simon (1989), the treatment program was designed to refuse
response rates of 20% (P0) and to provide a signiﬁcance level of
0.05 with a statistical power of 80% in assessing the activity of
the regimen as a 40% response rate (P1). The upper limit for
ﬁrst-stage drug rejection was four responses in the 18 evaluable
patients; the upper limit of second-stage rejection was 10 responses
in the 33 evaluable patients. Overall survival was deﬁned as the
interval between enrollment in this study and death or the ﬁnal
follow-up visit. Median overall survival was estimated by the
Kaplan–Meier analysis method (Kaplan and Meier, 1958).
RESULTS
Patient population and treatment
A total of 33 patients were enrolled in this study between March
31, 2000 and September 25, 2000. Patient characteristics are listed
in Table 1. The majority of patients were male (79%); median age
was 63 years. The most common histologic subtype was adenocar-
cinoma (64%). Most patients (76%) had stage IV disease or
recurrence after surgical resection.
A total of 115 courses were administered. The median number
of treatment courses was three (range: 1–6). Thirteen patients
experienced dose reduction because of omission of the treatment
on day 8 (n=7) and neutropenic fever grade 3 (n=6).
Efﬁcacy
There were 16 partial responses in 33 eligible patients and the
objective response rate was 48% (95% conﬁdence interval (CI):
31–66%) (Table 2). As described below, one patient was not
evaluable for response because of early death.
The median follow-up time was 25 months, and six patients
were still alive at the most recent follow up. The median time to
response was 1.4 months (range 0.6–2.6 months). The median
duration of response was 3.5 months (1.2–15.6 months). The
median time to disease progression was 5.0 months (95% CI:
3.7–6.3 months). The median survival time was 13.5 months
(95% CI: 10.6–16.4 months), and the one-year survival rate was
61% (Figure 1).
Safety and toxicity
Toxicity was evaluated in all enrolled patients and in all cycles. The
most common toxicity was haematologic (Table 3). Grade 4
neutropenia occurred in 72% of the patients and 35% of the
courses. Febrile neutropenia occurred in 42% of patients. There
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1360–1364was one toxic death, attributed to neutropenic fever and haemop-
tysis, in a 68-year-old male. The pre-treatment blood studies
showed a leukocyte count of 8600 mm
73, platelet count of
225000 mm
73, and serum creatinine level of 1.0 mg ml
71. The
blood studies on day 8 showed a leukocyte count of
2900 mm
73, platelet count of 84000 mm
73, and serum creatinine
level of 1.4 mg dl
71. These levels met the criteria, and the agents
were administered on day 8. On day 11, the leukocyte count was
3200 mm
73, and the platelet count 49000 mm
73. Intravenous
ﬂuids had been administered on day 13 because of nausea and
poor food intake. On day 14, the leukocyte count fell to
800 mm
73 with a neutrophil count of 60 mm
73, the platelet
count was 29000 mm
73, and serum creatinine level was
2.8 mg ml
71. Fever, haemoptysis, and dyspnoea developed, and
arterial blood gas analysis showed a PaO2 of 45.7 torr. Transbron-
chial intubation was performed to allow artiﬁcial ventilation. The
respiratory failure worsened, and the patient died on day 14.
Autopsy revealed diffuse pulmonary haemorrhage secondary to
bacterial abscesses and vasculitis in both lungs.
Grade 3 nausea was observed in seven patients (21%) and
required intravenous infusions. Grade 2 creatinine elevation was
observed in four patients (12%). Vinorelbine and gemcitabine
alone were administered to one patient during courses 5 and 6
because of serum creatinine elevation to above 1.5 mg dl
71.
Performance status deteriorated in 16 patients, and chemotherapy
was terminated in ﬁve of them because of poor performance status.
Second-line chemotherapy
A total of 13 patients received second-line chemotherapy. Eleven
patients received docetaxel-based chemotherapy. One patient
received ZD-1839 (Iressa
1), a tyrosine-kinase inhibitor. The
remaining patient received the same regimen of chemotherapy
(vinorelbine, gemcitabine, and cisplatin).
DISCUSSION
We reported a phase II study designed to evaluate the efﬁcacy and
safety of triplet chemotherapy containing vinorelbine, gemcitabine,
and cisplatin in patients with advanced NSCLC. There are several
reports on this triplet chemotherapy, mainly in Europe (Table 4).
Italian and Spanish trials showed that grade 3 or 4 neutropenia
occurred in 30% to 45% of patients, and that neutropenic fever
occurred in 5–27% of patients (Comella et al, 1999, 2000; Alberola
et al, 2001; Comella, 2001). In our own trial, however, grade 3 or 4
neutropenia and neutropenic fever occurred in 97% and 42%,
respectively, of patients. This frequent febrile neutropenia is not
acceptable. In the Italian trials, full doses of chemotherapy were
given if the neutrophil and platelet counts on the day of treatment
were 52000 mm
73 and 5100000 mm
73, and chemotherapy was
given at 75% of the planned dose if grade 1 myelotoxicity (except
anaemia) on the World Health Organization (WHO) grade scale
C
l
i
n
i
c
a
l
Table 1 Patient characteristics
Characteristic Number of Patients
Patients enrolled 33
Sex
Male 26
Female 7
Age (years)
Median 63
Range 37–72
PS status
03
13 0
Stage
IIIB 8
IV 23
Recurrence after surgery 2
Histologic type
Adenocarcinoma 21
Squamous cell carcinoma 8
Large cell carcinoma 4
Table 2 Efﬁcacy of triplet chemotherapy with vinorelbine, gemcitabine,
and cisplatin in patients with stage IIIB or IV NSCLC
Type of response Number of patients (%)
Complete (CR) 0 (0)
Partial (PR) 16 (48)
CR+PR 16 (48)
95% CI 31–66
Stable disease 16 (48)
Progression 0 (0)
Not evaluable 1 (3)
100
75
50
25
0
Survival time (months)
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%
)
30 24 18 12 6 0
Figure 1 Overall survival of all patients (n=33) was calculated according
to the Kaplan–Meier method. The median survival time was 13.5 months
(95% CI: 10.6–16.4 months), and the one-year survival rate was 61%
Table 3 Maximum toxicity grades associated with vinorelbine, gemcita-
bine, and cisplatin in 33 patients with NSCLC
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity No. % No. % No. % No. %
Leukopenia 0 0 5 15 21 64 7 21
Neutropenia 0 0 1 3 8 24 24 73
Anaemia 5 15 15 45 10 30 2 6
Thrombocytopaenia 3 9 10 30 20 61 0 0
Nausea 13 39 6 18 7 21 – –
Vomiting 6 18 4 12 2 6 0 0
Diarrhoea 5 15 1 3 1 3 0 0
Infection – – – – 2 6 0 0
Neutropenic fever – – – – 13 39 1 3
Fever (no infection) 3 9 3 9 0 0 0 0
Allergy 0 0 2 6 0 0 0 0
Eruption 2 6 2 6 0 0 0 0
Neurotoxicity 6 18 0 0 0 0 0 0
A S T 8 2 4130000
ALT 12 36 1 3 0 0 0 0
Serum creatinine 9 27 4 12 0 0 0 0
Hyponatremia 26 79 – – 6 18 0 0
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British Journal of Cancer (2002) 87(12), 1360–1364 ã 2002 Cancer Research UKwas present on day 8. Grade 1 myelotoxicity on the WHO grade
scale means leukocyte, neutrophil, and platelet counts of 3000–
3999 mm
73, 1500–1999 mm
73, and 75000–99999 mm
73,
respectively (Miller et al, 1981). By contrast, our criteria for admin-
istration of the agents on day 8 were a leukocyte count of
2500 mm
73 and a platelet count of 50000 mm
73 or more. Grade
3 or 4 neutropenic fever occurred in 14 of the 33 patients (42%)
and in 17 of the 115 courses (15%). Leukocyte counts less than
2500 mm
73 on day 8 of the course occurred in 16 courses, counts
of 2500–3000 mm
73 in 20 courses, and of 3000 mm
73 or more
in 79 courses. Grade 3 or 4 neutropenic fever was observed in 0
(0%), 6 (30%), and 11 (14%) of these courses, respectively. The
criteria should be changed to leukocyte counts of 4000 mm
73 or
more for full doses of the agents and 3000–3999 mm
73 for 75%
doses. If the leukocyte and platelet counts on day 8 do not meet
the criteria, chemotherapy should be postponed to day 15. These
differences in criteria for administration of the agents on day 8
seemed to be responsible for the severe neutropenia and neutrope-
nic fever in our trial.
The 48% response rate in our study was equivalent to the rate in
the previous study. The 13.5-month median survival time and 61%
1-year survival rate in our study seem higher than in previous
studies (Comella et al, 1999, 2000; Ginopoulos et al, 1999; Alberola
et al, 2001; Comella, 2001; Hesketh et al, 2001), and the differences
are probably attributable to patient selection. Female patients
accounted for 21% in our trial, as opposed to only 3–14% in
the European trials (Alberola et al, 2001; Comella et al, 1999,
2000, Comella, 2001; Ginopoulos et al, 1999). The female patients
survived statistically longer than the males in our trial, with 1-year
survival rates of 86% and 54%, respectively (P=0.035, log-rank
test). No PS 2 patients were included in our trial. On the other
hand, the Spanish trial included 14% of PS 2 patients. The Italian
trial demonstrated that triplet chemotherapy containing cisplatin,
gemcitabine, and vinorelbine or paclitaxel was superior to standard
doublet chemotherapy containing cisplatin and vinorelbine, or
gemcitabine (Comella et al, 2000; Comella, 2001). The Spanish
trial, however, did not conﬁrm the superiority of either triplet
chemotherapy (Alberola et al, 2001). More randomised trials
comparing triplets containing new agents with their corresponding
doublets are warranted.
One patient developed life-threatening haemoptysis. Autopsy
demonstrated diffuse pulmonary haemorrhage due to bacterial
abscesses and vasculitis in both lungs. As far as we have been able
to determine, this is the ﬁrst report of haemoptysis after adminis-
tration of vinorelbine, gemcitabine, and cisplatin.
Cisplatin was administered on days 1 and 8 in our trial and the
Italian trial, whereas 75–100 mg m
72 was administered on day 1
in the Spanish and Greek trial (Ginopoulos et al, 1999; Alberola et
al, 2001). Divided doses of cisplatin reduce the volume of ﬂuid
infused for hydration and make administration to outpatients
more convenient.
In conclusion, triplet chemotherapy containing vinorelbine,
gemcitabine, and cisplatin is effective in the treatment of
chemotherapy-na ¨ive patients with advanced NSCLC, but produces
unacceptable frequent febrile neutropenia. This triplet regimen
should not be taken forward.
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